BACKGROUND: Mesonephric-like adenocarcinoma (M-LAC) is a rare, recently described tumor occurring in the uterine corpus and ovary, which shares the same morphological and immunohistochemical features with the more common mesonephric adenocarcinoma (MAC), which mostly arises the uterine cervix. Despite the similarities between these tumors, the histogenesis of M-LAC is still disputable. CASE PRESENTATION: Sixty-one-year-old woman presented with an advanced tumor of the left ovary with intraabdominal spread and liver metastases. After receiving 5 cycles of neoadjuvant chemotherapy, she underwent a hysterectomy with bilateral salpingo-oophorectomy, and resection of the liver metastasis, omentum, and appendix. Histologically, the ovarian tumor consisted of two components, whose morphology and immunohistochemical results were typical of either a serous borderline tumor (immunohistochemical positivity for PAX8, WT1, ER and PR) or a mesonephric-like carcinoma (immunohistochemical positivity for PAX8, TTF1 and GATA3). Only the component of the mesonephric-like adenocarcinoma metastasized to the omentum and liver. A molecular analysis with a panel of 271 genes (size 1020 kbp) was performed separately on samples from the borderline tumor, primary ovarian mesonephric-like adenocarcinoma, and liver metastasis. The results showed the clonal origin of all samples, which shared the same KRAS (NM_004985.3:c.34G > T, p.(G12C)) and PIK3CA (NM_006218.2:c.1633G > A, p.(E545K)) somatic mutations. Moreover, in the sample from the primary mesonephric-like carcinoma and its liver metastasis a likely pathogenic somatic MYCN mutation (NM_005378.4:c.131C > T, p.(P44L) was found. In all samples, the deletion of exons 9-10 in the CHEK2 gene was present, which is in concordance with the previously performed genetic testing of the blood specimen which revealed the hereditary CHEK2 mutation in this patient. CONCLUSIONS: Our result support the theory that at least some mesonephric-like ovarian adenocarcinomas are of Müllerian origin. The serous borderline tumor seems to be a precursor of mesonephric-like adenocarcinoma, which has been proven in our case by both tumors sharing the same mutations, and the presence of cumulative molecular aberrations in the mesonephric-like adenocarcinoma.

Gynecologic Oncology Center Department of Obstetrics and Gynecology 1st Faculty of Medicine Charles University and General University Hospital Prague Apolinarska 18 12808 Prague 2 Czech Republic

Institute of Pathology 1st Faculty of Medicine Charles University and General University Hospital Prague Studnickova 2 12800 Prague 2 Czech Republic

Zobrazit více v PubMed

Euscher ED, Bassett R, Duose DY, Lan C, Wistuba I, Ramondetta L, et al. Mesonephric-like carcinoma of the endometrium: a subset of endometrial carcinoma with an aggressive behavior. Am J Surg Pathol. 2020;44(4):429–443. PubMed

Clement PB, Young RH, Keh P, Ostor AG, Scully RE. Malignant mesonephric neoplasms of the uterine cervix. A report of eight cases, including four with a malignant spindle cell component. Am J Surg Pathol. 1995;19(10):1158–1171. doi: 10.1097/00000478-199510000-00006. PubMed DOI

Ferry JA, Scully RE. Mesonephric remnants, hyperplasia, and neoplasia in the uterine cervix. A study of 49 cases. Am J Surg Pathol. 1990;14(12):1100–1111. doi: 10.1097/00000478-199012000-00002. PubMed DOI

Horn LC, Hohn AK, Krucken I, Stiller M, Obeck U, Brambs CE. Mesonephric-like adenocarcinomas of the uterine corpus: report of a case series and review of the literature indicating poor prognosis for this subtype of endometrial adenocarcinoma. J Cancer Res Clin Oncol. 2020;146(4):971–983. doi: 10.1007/s00432-019-03123-7. PubMed DOI PMC

Zhang L, Cai Z, Ambelil M, Conyers J, Zhu H. Mesonephric adenocarcinoma of the uterine Corpus: report of 2 cases and review of the literature. Int J Gynecol Pathol. 2019;38(3):224–229. doi: 10.1097/PGP.0000000000000493. PubMed DOI

Chapel DB, Joseph NM, Krausz T, Lastra RR. An ovarian adenocarcinoma with combined low-grade serous and Mesonephric morphologies suggests a Mullerian origin for some Mesonephric carcinomas. Int J Gynecol Pathol. 2018;37(5):448–459. doi: 10.1097/PGP.0000000000000444. PubMed DOI

McCluggage WG, Vosmikova H, Laco J. Ovarian combined low-grade serous and Mesonephric-like adenocarcinoma: further evidence for a Mullerian origin of Mesonephric-like adenocarcinoma. Int J Gynecol Pathol. 2020;39(1):84–92. doi: 10.1097/PGP.0000000000000573. PubMed DOI

Prat J. Staging classification for Cancer of the ovary, fallopian tube, and peritoneum: abridged republication of guidelines from the International Federation of Gynecology and Obstetrics (FIGO) Obstet Gynecol. 2015;126(1):171–174. doi: 10.1097/AOG.0000000000000917. PubMed DOI

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45(2):228–247. doi: 10.1016/j.ejca.2008.10.026. PubMed DOI

Hajkova N, Hojny J, Nemejcova K, Dundr P, Ulrych J, Jirsova K, et al. Germline mutation in the TP53 gene in uveal melanoma. Sci Rep. 2018;8(1):7618. doi: 10.1038/s41598-018-26040-0. PubMed DOI PMC

Montalvo N, Redroban L, Galarza D. Mesonephric adenocarcinoma of the cervix: a case report with a three-year follow-up, lung metastases, and next-generation sequencing analysis. Diagn Pathol. 2019;14(1):71. doi: 10.1186/s13000-019-0847-8. PubMed DOI PMC

Howitt BE, Nucci MR. Mesonephric proliferations of the female genital tract. Pathology. 2018;50(2):141–150. doi: 10.1016/j.pathol.2017.11.084. PubMed DOI

Kenny SL, McBride HA, Jamison J, McCluggage WG. Mesonephric adenocarcinomas of the uterine cervix and corpus: HPV-negative neoplasms that are commonly PAX8, CA125, and HMGA2 positive and that may be immunoreactive with TTF1 and hepatocyte nuclear factor 1-beta. Am J Surg Pathol. 2012;36(6):799–807. doi: 10.1097/PAS.0b013e31824a72c6. PubMed DOI

Na K, Kim HS. Clinicopathologic and molecular characteristics of Mesonephric adenocarcinoma arising from the uterine body. Am J Surg Pathol. 2019;43(1):12–25. doi: 10.1097/PAS.0000000000000991. PubMed DOI PMC

Howitt BE, Emori MM, Drapkin R, Gaspar C, Barletta JA, Nucci MR, et al. GATA3 is a sensitive and specific marker of benign and malignant Mesonephric lesions in the lower female genital tract. Am J Surg Pathol. 2015;39(10):1411–1419. doi: 10.1097/PAS.0000000000000471. PubMed DOI

Mirkovic J, Sholl LM, Garcia E, Lindeman N, MacConaill L, Hirsch M, et al. Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract. Mod Pathol. 2015;28(11):1504–1514. doi: 10.1038/modpathol.2015.103. PubMed DOI

Mirkovic J, McFarland M, Garcia E, Sholl LM, Lindeman N, MacConaill L, et al. Targeted genomic profiling reveals recurrent KRAS mutations in Mesonephric-like adenocarcinomas of the female genital tract. Am J Surg Pathol. 2018;42(2):227–233. doi: 10.1097/PAS.0000000000000958. PubMed DOI

McFarland M, Quick CM, McCluggage WG. Hormone receptor-negative, thyroid transcription factor 1-positive uterine and ovarian adenocarcinomas: report of a series of mesonephric-like adenocarcinomas. Histopathology. 2016;68(7):1013–1020. doi: 10.1111/his.12895. PubMed DOI